Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and
orthopedics company, today announced that Andres Cedron has joined
the company as Chief Legal Officer.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240416821173/en/
Andres Cedron, Chief Legal Officer for
Orthofix (Photo: Business Wire)
Cedron most recently served as Vice President and Corporate
Secretary at Stryker Corporation, a $20B+ global medical device
company. In his corporate officer position, Cedron oversaw
Stryker’s corporate governance, SEC compliance, mergers and
acquisitions, and ESG matters.
“With a broad breadth of experience in the medical device
industry and legal transactions, Andres is the perfect fit for this
important leadership role,” said Massimo Calafiore, President and
Chief Executive Officer of Orthofix. “His extensive understanding
of our business and the overall market will be an asset in helping
the company drive profitability and growth as we continue to power
Orthofix’s transformation.”
Cedron is known for his strong focus on scaling businesses and
accelerating performance and will lead Orthofix in a broad range of
corporate and commercial matters.
“I am thrilled to join such a talented leadership team and
organization of dedicated employees,” said Andres Cedron, Chief
Legal Officer. “This is an exciting time for the company, and I
look forward to helping Orthofix become an even stronger competitor
in the market.”
About Andres Cedron
Cedron brings nearly 20 years of executive legal experience to
Orthofix. In addition to his role as Vice President and Corporate
Secretary at Stryker, Cedron held leadership roles as Chief Legal
Counsel for Stryker’s $10B+ MedSurg and Neurotechnology Group, as
well as the company’s EMEA and Latin America regions. In addition,
Cedron served as President of Stryker’s Hispanic/Latino employee
resource group from 2019 to 2022, growing it from two to eight
chapters nationally and more than 1,000 members. He has extensive
expertise in regulatory and compliance frameworks, anti-corruption
programs, litigation management, and commercial legal strategies in
the medical device industry.
Before Stryker, Cedron started his career as a corporate
attorney at law firms in New York and Miami. Cedron holds a J.D.
from Columbia Law School and a B.A. from Colorado College.
As an inducement to enter into employment with Orthofix, Cedron
was granted (i) performance-based vesting restricted stock units
that settle 57,296 shares of common stock at target achievement,
(ii) time-based vesting restricted stock units that settle into
28,648 shares of common stock, and (iii) stock options to purchase
64,817 shares of common stock. The performance-based vesting
restricted stock units vest at the end of a three-year performance
period based on the Company’s total stockholder return relative to
an industry peer group index during such period, while the
time-based vesting restricted stock units vest in equal tranches
over three years. The stock options vest upon achievement of both
service- and performance-based criteria, whichever is the later of
(a) the date certain service-based conditions are met (which will
be met over three years) and (b) the date that the average closing
price of the Company’s common stock over a one-month calendar
period has been equal to or great than 150% of the closing price of
the Company’s common stock on the grant date. The grants, which
were approved by Orthofix’s Board of Directors, were made under
standalone inducement award agreements approved pursuant to NASDAQ
Marketplace Rule 5635(c)(4).
About Orthofix
Orthofix is a leading global spine and orthopedics company with
a comprehensive portfolio of biologics, innovative spinal hardware,
bone growth therapies, specialized orthopedic solutions, and a
leading surgical navigation system. Its products are distributed in
more than 60 countries worldwide.
The Company is headquartered in Lewisville, Texas, where it
conducts general business, product development, medical education
and manufacturing, and has primary offices in Carlsbad, CA, with a
focus on spine and biologics product innovation and surgeon
education, and Verona, Italy, with an emphasis on product
innovation, production, and medical education for orthopedics. The
combined Company’s global R&D, commercial and manufacturing
footprint also includes facilities and offices in Irvine, CA,
Toronto, Canada, Sunnyvale, CA, Wayne, PA, Olive Branch, MS,
Maidenhead, UK, Munich, Germany, Paris, France and São Paulo,
Brazil.
Forward-Looking Statements
This news release may include forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934,
as amended, and Section 27A of the Securities Act of 1933, as
amended. In some cases, you can identify forward-looking statements
by terminology such as “may,” “will,” “should,” “expects,” “plans,”
“anticipates,” “believes,” “estimates,” “projects,” “intends,”
“predicts,” “potential,” “continue” or other comparable
terminology. Orthofix cautions you that statements included in this
news release that are not a description of historical facts are
forward-looking statements that are based on the Company’s current
expectations and assumptions. Each forward-looking statement
contained in this news release is subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statement. Applicable risks
and uncertainties include, among others: the ability of newly
launched products to perform as designed and intended and to meet
the needs of surgeons and patients, including as a result of the
lack of robust clinical validation; and the risks identified under
the heading “Risk Factors” in Orthofix Medical Inc.’s Annual Report
on Form 10-K for the fiscal year ended December 31, 2023, which was
filed with the Securities and Exchange Commission (SEC) on March 5,
2024. The Company’s public filings with the Securities and Exchange
Commission are available at www.sec.gov. You are cautioned not to
place undue reliance on forward-looking statements, which speak
only as of the date when made. Orthofix does not intend to revise
or update any forward-looking statement set forth in this news
release to reflect events or circumstances arising after the date
hereof, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240416821173/en/
Media Relations Denise Landry DeniseLandry@orthofix.com
214.937.2529
Investor Relations Louisa Smith, Gilmartin Group
IR@orthofix.com
Orthofix Medical (NASDAQ:OFIX)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025
Orthofix Medical (NASDAQ:OFIX)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025
